Skip to main content
. Author manuscript; available in PMC: 2017 Aug 8.
Published in final edited form as: Cancer. 2016 Nov 14;123(6):1011–1017. doi: 10.1002/cncr.30445

Table 2.

Efficacy analysis.

Outcome measure All Patients (n = 30)
Number % 95% CI
Response
 Yes 14 48.3
 No 15 51.7
Type of response
 Complete response 1 3.4
 Partial response 13 44.8
 Stable disease 10 34.4
 Progressive disease 5 17.2
 Inevaluable 1 3.4
Probability of progression free survival at 6 months 68 52 – 88
Median progression free survival, months 8.7 4.9 – 10.5
Median overall survival, months 12.9 9.2 – 19.7